Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter S Hall

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 20, 2017
Real-world data for efficient health technology assessmentPeter S Hall
Breast Care (Basel, Switzerland)|June 1, 2017
Accurate Measurement of Financial Toxicity Is a Prerequisite to Finding a RemedyAdam Martin, Peter S Hall
Pharmacoeconomics|February 26, 2013
What evidence is there for the reimbursement of personalised medicine?Peter S Hall, Christopher McCabe
European Journal of Cancer (Oxford, England : 1990)|December 2, 2008
Current perspective - trastuzumabPeter S Hall, David A Cameron
Pharmacoeconomics|February 17, 2016
NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big DataOwen A Johnson, Peter S Hall, Claire Hulme
The Lancet. Oncology|June 2, 2009
Lapatinib for inflammatory breast cancerPeter S Hall, Andrew Hanby, David A Cameron
JAMA Oncology|September 2, 2021
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population-ReplyPeter S Hall, David A Cairns, Matthew T Seymour
Systematic Reviews|September 17, 2018
Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studiesEwan Gray, Anna Donten, Katherine Payne, et al.
Cost Effectiveness and Resource Allocation : C/E|March 15, 2019
Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage <i>HER2</i>-positive breast cancerNoga Gershon, Yakir Berchenko, Peter S Hall, et al.
Journal of the National Cancer Institute|December 6, 2011
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancerPeter S Hall, Christopher McCabe, Robert C Stein, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|May 20, 2017
Real-world data for efficient health technology assessmentPeter S Hall
Breast Care (Basel, Switzerland)|June 1, 2017
Accurate Measurement of Financial Toxicity Is a Prerequisite to Finding a RemedyAdam Martin, Peter S Hall
Pharmacoeconomics|February 26, 2013
What evidence is there for the reimbursement of personalised medicine?Peter S Hall, Christopher McCabe
European Journal of Cancer (Oxford, England : 1990)|December 2, 2008
Current perspective - trastuzumabPeter S Hall, David A Cameron
Pharmacoeconomics|February 17, 2016
NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big DataOwen A Johnson, Peter S Hall, Claire Hulme
The Lancet. Oncology|June 2, 2009
Lapatinib for inflammatory breast cancerPeter S Hall, Andrew Hanby, David A Cameron
JAMA Oncology|September 2, 2021
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population-ReplyPeter S Hall, David A Cairns, Matthew T Seymour
Systematic Reviews|September 17, 2018
Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studiesEwan Gray, Anna Donten, Katherine Payne, et al.
Cost Effectiveness and Resource Allocation : C/E|March 15, 2019
Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage <i>HER2</i>-positive breast cancerNoga Gershon, Yakir Berchenko, Peter S Hall, et al.
Journal of the National Cancer Institute|December 6, 2011
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancerPeter S Hall, Christopher McCabe, Robert C Stein, et al.
Pageof 6